NCT04543461 American Lung Association (ALA) Lung Health Cohort
| NCT ID | NCT04543461 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | Lung Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2021-10-29 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,000 participants in total. It began in 2021-10-29 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.
Eligibility Criteria
Inclusion Criteria: 1- Age 25-35 years at the time of the baseline examination 2- Able to read and understand English or Spanish 3 -Has a social security number 4- Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination. Note: Individuals who are residents of the US who have temporarily spent time living outside of the US during the last 12 months (e.g., student exchange program, military posting) are eligible for participation. 5- Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant Exclusion Criteria: 1. Severe asthma, which is defined as any of the following: 1. Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; Medium dose = \>250 fluticasone, propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). We will accept low-dose ICS/LABA or medium dose ICS. OR 2. 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months OR 3. One asthma hospitalization in the past 12 months 2. History of any chronic lung disease other than asthma including but not limited to COPD, cystic fibrosis, pulmonary fibrosis, pulmonary hypertension 3. Current pregnancy 4. History of cancer other than non-melanoma skin cancer 5. Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heart disease) 6. Inability to comply with study procedures, including 1. Inability or unwillingness to provide informed consent 2. Inability to perform study measurements 3. Inability to be contacted by phone (via calls and/or text messaging) or email 7. Any condition in the opinion of the physician that puts the participant at risk by participating in the study (e.g., serious respiratory illness requiring antibiotics or steroids or severe fever at the time of the study visit). 8. Institutionalization
Contact & Investigator
Ravi Kalhan, MD
PRINCIPAL INVESTIGATOR
Northwestern University
Frequently Asked Questions
Who can join the NCT04543461 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, up to 35 Years, studying Lung Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04543461 currently recruiting?
Yes, NCT04543461 is actively recruiting participants. Contact the research team at esugar2@jhu.edu for enrollment information.
Where is the NCT04543461 trial being conducted?
This trial is being conducted at Birmingham, United States, Tucson, United States, Los Angeles, United States, San Francisco, United States and 11 additional locations.
Who is sponsoring the NCT04543461 clinical trial?
NCT04543461 is sponsored by Johns Hopkins University. The principal investigator is Ravi Kalhan, MD at Northwestern University. The trial plans to enroll 4,000 participants.